Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors

#2869

Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.

Aim(s): Evaluation of the possibility of increasing antitumor efficacy using a combination of targeted therapy and somatostatin analogues.

Materials and methods: Patient received the targeted therapy with the oral protein kinase inhibitor Sunitinib at a dose of 37.5 mg daily and biotherapy with somatostatin analogue – Lanreotide as a monthly subcutaneous injection.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Emelianova G, Dronova E,

Keywords: neuroendocrine tumor, pancreas, sunitinib, somatostatin analogues,